SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?


To: LemurHouse who wrote (265)11/20/1998 9:40:00 AM
From: Anthony Wong  Respond to of 656
 
09:21 ET Immunex Corp. (IMNX) 86 15/16: Salomon Smith Barney raises its price target from $100 to $122 a share on positive views of Enbrel sales. (From briefing.com)



To: LemurHouse who wrote (265)11/20/1998 10:31:00 AM
From: Anthony Wong  Read Replies (1) | Respond to of 656
 
Immunex Corp. Cut to 'Market Perform' at BT Alex. Brown

Bloomberg News
November 20, 1998, 10:01 a.m. ET

Princeton, New Jersey, Nov. 20 (Bloomberg Data) -- Immunex Corp. (IMNX US)
was downgraded to ''market perform'' from ''buy'' by analyst Kevin C. Tang at
BT Alex. Brown Incorporated.

-- Andrew Bekoff in Princeton, New Jersey, (609)279-3652